BioSpace News Archive

PharmAla Biotech Holdings Inc. is pleased to announce that is has issued a shipment of its GMP LaNeo MDMA to Mind Medicine Australia, a charity which seeks to alleviate the suffering caused by mental illness in Australia through expanding treatment using psychedelic molecules.

Cantex Pharmaceuticals today announced the publication in the peer-reviewed journal, npj Breast Cancer, a Nature Portfolio journal published in partnership with Breast Cancer Research Foundation, with results from in vitro and in vivo models for triple-negative breast cancer showing suppression of metastasis and tumor progression by RAGE inhibition.

Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform announces an exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC, a multinational pharmaceutical company for the Middle East and North Africa.

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, August 14, 2023 at 8:30 a.m. Eastern Daylight Time to review second-quarter 2023 financials and provide corporate updates.

Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, reported financial results for the second quarter ended June 30, 2023.

NeurAxis, Inc., a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, highlighted current commercial insurance coverage policies for its IB-Stim™ therapy, with a total of 4.75 million lives covered, including:

ChromaCode, Inc. announced a strategic partnership with Protean BioDiagnostics Inc., a CAP/CLIA-accredited, high-complexity laboratory specializing in developing and commercializing advanced cancer diagnostic technologies.

Virpax® Pharmaceuticals, Inc. announced that it has filed a new provisional patent application with the United States Patent and Trademark Office entitled “NSAID Formulation and Method” related to its Epoladerm™ product candidate.

BioFlyte announced that it raised $5.4M in new financing led by Scout Ventures and Cottonwood Technology Fund with additional funding from New Mexico Vintage Fund.

Marius Pharmaceuticals (Marius) and Smartway Pharmaceuticals (Smartway) are pleased to announce their strategic partnership, aimed at addressing the pressing global issue of hypogonadism through the launch of a comprehensive Early Access Program for KYZATREX™ (testosterone undecanoate).